Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Servier and generics firms to appeal EU verdict on perindopril 'sweetheart' deals

This article was originally published in SRA

Executive Summary

The European Commission has imposed fines totaling Euros 427.7 million on Servier and five producers of generic medicines for anti-competitive practices – a decision that the French drug maker says sets a "regrettable precedent" for industries that rely on intellectual property1,2.

You may also be interested in...



EU Servier Court Ruling 'Reduces Competition Law Risks For Pharma'

The EU’s General Court judgement in the Servier pay-for-delay case will put more pressure on competition authorities to show evidence of alleged abuse of a dominant position.

Teva 'Pay-For-Delay Case Will Keep Courts Busy For Years'

Once again the European Commission has the marketing practices of the pharmaceutical industry in its sights, with Teva the latest company in the spotlight for an alleged 'pay-for-delay' agreement over the sleep disorder drug modafinil.

Teva 'Pay-For-Delay Case Will Keep Courts Busy For Years'

Once again the European Commission has the marketing practices of the pharmaceutical industry in its sights, with Teva the latest company in the spotlight for an alleged 'pay-for-delay' agreement over the sleep disorder drug modafinil.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS117864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel